Hair regrowth after 13 weeks using topical minoxidil, oral finasteride, peptide shampoo, serum, and a red light hat. Some growth is attributed to a recent hair transplant.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
People's experiences with Pyrilutamide as a hair loss treatment, including anecdotal evidence of regrowth and reduced scalp itch when used in conjunction with Finasteride and Minoxidil.
The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.
A 31-year-old male shared his 3-year progress using finasteride 1 mg daily, with additional treatments including nutrafol, multivitamins, vitamin D, marine collagen, PRP scalp injections, micro-needling, and Nizoral. He experienced temporary libido issues but currently has no side effects.
The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
The user plans to use a "nuclear protocol" for hair improvement, including topical minoxidil 12.5%, topical finasteride 0.1%, and tretinoin 0.05%, with microneedling once a week. They have seen improvements with minoxidil and are seeking opinions on their approach to achieve thicker hair.
Peppermint Essential Oil (PEO) was discussed for its hair regrowth effects on shaved mice after 4 weeks. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.
The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.
The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
The user is using Minoxidil, Finasteride, microneedling, and plans to add low-level laser therapy (LLLT) to treat hair thinning. They shared progress pictures showing results from May 8th to June 7th.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
The user has been treating hair loss since age 17, now 29, using a daily regimen of topical Minoxidil/Finasteride, Pyrilutamide, Minoxidil, and weekly microneedling. They chose a low dose of Finasteride due to past side effects and report that Pyrilutamide has stopped hair shedding and they believe there is some regrowth and increased thickness.
The user has been using finasteride, dutasteride, and minoxidil without success and is considering a comprehensive blood test to explore other causes of hair loss. They are unsure about the necessity and cost of the extensive tests and are seeking advice on whether to proceed with the full panel or focus on specific tests.
The user "Bishiop" shared a progress update on their hair density and strength after adding Minoxidil to their routine. They are also using Finasteride and microneedling. They hope to fill in their hairline by the end of the summer.
The post discusses using Carnitine Tartrate, Potassium Chloride, and Niacin to reduce hair shedding, with the user experiencing significant improvement. The user also suggests considering a ketogenic/paleo diet for those with insulin resistance-related hair loss.
PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.